{"brief_title": "Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney", "brief_summary": "The purpose of this study is to determine whether treatment with Belatacept (BMS-224818) is as efficacious as treatment with cyclosporine at preventing acute rejection and with a superior safety/tolerability profile (better kidney function and blood pressure, fewer lipid problems, less diabetes mellitus).", "condition": "Renal Transplantation", "intervention_type": "Drug", "intervention_name": "Corticosteroids", "description": "Corticosteroids given daily, orally or intravenously (IV). Day of transplant (Day 1): methylprednisolone, 500 mg, given IV on arrival in operating room; Day 2: methylprednisolone, 250 mg, given IV once daily; Day 3: prednisone, 100 mg, given orally once daily; Day 4: prednisone, 50 mg, given orally once daily; Days 5 through 30: prednisone, 25 mg, given orally once daily; Days 31-44: prednisone, 22.5 mg, given orally once daily; Days 45-58: prednisone, 20 mg, given orally once daily", "arm_group_label": "Cyclosporine regimen", "other_name": "The cyclosporine used in this study will be in the modified formulation with enhanced bioavailability.", "criteria": "Key inclusion criteria - Recipients of first kidney transplant Key exclusion criteria - Those at high risk for acute allograft rejection, including those who receive a second or more renal transplant, those with a history of panel reactive antibody levels >20%, and those considered by investigators to be at relatively higher risk for acute rejection - Human leukocyte antigen-identical donor-recipient pairs - Cold ischemia time >36 hours (donor kidney) - Participants who are positive for hepatitis C antibody, on polymerase chain reaction, for hepatitis B surface antigen, and for human immunodeficiency virus - A positive purified protein derivative tuberculosis test (test performed within 1 year of enrollment), unless previously vaccinated with Bacille-Calmette-Gu\u00e9rin or those who had a history of adequate chemoprophylaxis - Any active infection that would normally exclude transplantation - Recipients of multiple organ transplants - Donor age >60 or <6 years or donors whose hearts were not beating - Recipients with underlying renal disease of (due to risk of rapid disease recurrence in the allograft): focal segmental glomerulosclerosis, Type I or II membranoproliferative glomerulonephritis, or hemolytic uremic syndrome/ thrombotic thrombocytopenic purpura - A positive T-cell lymphocytoxic crossmatch using donor lymphocytes and recipient serum - A history of true allergy to intravenous iodinated roentgenographic contrast agents - Participants with life expectancy severely limited by disease state or other underlying medical condition - A history of cancer (other than nonmelanoma skin cell cancers cured by local resection) within the last 5 years - Mammogram film with any clinically significant abnormality requiring further investigation or biopsies - History of substance abuse (drug or alcohol) or psychotic disorders that were not compatible with adequate study follow-up - A currently functioning, nonrenal transplant - Previous treatment with basiliximab for any reason - Active peptic ulcer disease, chronic diarrhea, or gastrointestinal malabsorption - Those who had used any investigational drug within 30 days before the Day 1 visit.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00035555.xml"}